Page 1

SARTORIUS Göttingen , October 20 , 2021 Earnings Release Sartorius grows dynamically and profitably Substantial double - digit increases in sales and earnings ■ Order intake up 72.3 percent ; sales revenue up 53.9 percent ; underlying EBITDA margin 34.3 percent Both divisions with strong double - digit growth ; significant demand momentum generated by the production of coronavirus vaccines and test kits as well as excellent development of acquisitions Forecast raised at the beginning of July for 2021 confirmed The life science group Sartorius has continued to grow dynamically and profitably . For the nine - month reporting period of 2021 , the company listed on the DAX since September recorded significant double - digit growth rates in sales and earnings . " In the first nine months of the year , high demand for innovative technologies for efficient development and production of biopharmaceuticals has led to the expected very dynamic development of our business . Additional momentum related to the manufacture of coronavirus vaccines and test kits was significant , but not dominant . We expanded our product portfolio for use in the production of cell and gene therapeutics as well as vaccines by taking over a majority stake in CellGenix and acquiring the cell culture media specialist Xell , " said Joachim Kreuzburg , Chairman of the Board of Directors and CEO . In addition , he confirmed the forecast for the current year . " We are optimistic about the further development of our business , are driving our extensive capacity expansion and recruitment programs full steam ahead , and confirm our full - year forecast , " emphasized Kreuzburg . Business development of the Group Group sales revenue surged by 53.9 percent to around 2,527 million euros in constant currencies ( reported : +50.4 percent ) . The majority of this growth was attributable to strong organic expansion of the core businesses of both divisions and in all regions . Acquisitions² added around 6 percentage points to the increase in sales revenue , and growth related to the development and production of coronavirus vaccines and test kits was about 21 percentage points . Order intake¹ grew even more dynamically , up 72.3 percent in constant currencies to 3,286 million euros ( of which around 20 percentage points were attributable to the coronavirus pandemic and around 8 percentage points to acquisitions ; reported : +68,0 percent ) . Between January and September 2021 , underlying EBITDA¹ grew strongly by 77.3 percent to 866 million euros while the corresponding margin rose to 34.3 percent ( 9M 2020 : 29.1 percent ) . This increase was influenced by economies of scale and by partially deferred cost development , for example , as a result of the low number of business trips and underproportionate new hires in non - production areas due to the pandemic . These trends have started to abate as the coronavirus - related restrictions have progressively eased . Relevant net profit¹ for the Sartorius Group surged by 92.7 percent to 407 million euros ; earnings 1 | 10